ARTICLE | Clinical News
Yeliva: Phase I final data
July 11, 2016 7:00 AM UTC
Final data from 16 evaluable patients with advanced solid tumors in an open-label, U.S. Phase I trial showed that once-daily oral Yeliva led to 1 partial response and 6 cases of stable disease. The pa...